Development of [64Cu]-DOTA-anti-CD20 for targeted therapy

Jalilian, Amir Reza; Mirsadeghi, Leila; Yari-Kamrani, Y.; Rowshanfarzad, Pejman; Kamali-Dehghan, Mohsen; Sabet, Mahsheed

doi:10.1007/s10967-006-6961-6

Cited by 18 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Due to our recent works on the labeling and use of various biologically active molecules with cyclotron-derived radioisotopes [11,12], we were interested in radiolabeling of SPION samples for the visualization of the tracer alterations in nanoparticle attachment biologically and the possibility of the use of this alteration for targeting imaging/therapeutic radionuclides specifically to certain organs.…”

Section: Introductionmentioning

confidence: 99%

Preparation and biological evaluation of [67Ga]-labeled-superparamagnetic nanoparticles in normal rats

Jalilian¹,

Panahifar

Akhlaghi³

et al. 2009

Radiochimica Acta

Self Cite

View full text Add to dashboard Cite

Gallium-67 / Superparamagnetic iron oxide nanoparticles / Radiolabeling / Stability / BiodistributionSummary. Gallium-67 labeled superparamagnetic iron oxide nanoparticles ([ 67 Ga]-SPION were prepared and evaluated for their altered biodistribution in normal rats. Superparamagnetic iron oxide nanoparticles (SPION) with narrow size distribution were synthesized by a co-precipitation technique using ferrous salts at Fe 3+ /Fe 2+ = 2 molar ratio followed by structure identification using XRD, TGA, DSC, VSM, HRSEM, TEM and FT-IR techniques (≈ 5 nm diameter). In order to trace SPION bio-distribution, the radiolabeled iron oxide nanoparticles were prepared using 67 Ga with a high labeling efficiency (over 96%, RTLC method) and they also showed an excellent stability at room temperature for at least 4 d. The biodistribution of the radiolabeled SPION was checked in normal male rats up to 24 h compared to free Ga 3+ cation biodistribution. The data strongly support the alteration of the tracer accumulation in reticuluendothelial system while the stability of the complex is highly retained.

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation and biological evaluation of [67Ga]-labeled-superparamagnetic nanoparticles in normal rats

Jalilian¹,

Panahifar

Akhlaghi³

et al. 2009

Radiochimica Acta

Self Cite

View full text Add to dashboard Cite

show abstract

“…The synthesis; structure, antitumor property, toxicity and glutathione (GSH) depletion property in vivo of the NHAG copper complex has also been reported previously [12]. Regarding these properties development of a possible copper tracer using this complex seemed interesting to us based on our recent experiences on radiocopper production via nat Zn(p,x) 61 Cu [13] and developing important Cu-radiopharmaceuticals in our research group [14,15].…”

Section: Introductionmentioning

confidence: 58%

Synthesis and Preclinical Studies of [61Cu]-N-(2-hydroxyacetophenone)glycinate as a Possible PET Radiopharmaceutical

Jalilian¹,

Sadeghi

Zandi

et al. 2008

Sci. Pharm.

View full text Add to dashboard Cite

Zn(p,x) 61 Cu (180μA proton irradiation, 22MeV, 3.2h) and purified by a ion chromatography method. [ 61 Cu]NHAG radiochemical purity was >98% and >99.9% by RTLC and HPLC methods respectively after purification by SPE. [ 61 Cu]NHAG was administered into normal and tumor bearing mice followed by biodistribution studies up to 180 minutes. The best tumor accumulation was observed by animal sacrification after 120 min (tumor/muscle and tumor/blood ratios were 25.6 and 3.4 respectively). [ 61 Cu]NHAG is a potential PET radiotracer for tumor imaging.

show abstract

“…In continuation of our previous works on the production and application of various radiolabeled antibodies [12][13][14], in this work, we report the production, chromatographic behavior and biodistribution of a 46 Sc, DOTA-antiCD20 immunoconjugate, for further radioimmunotherapeutic studies using 46 Sc. 46 Sc was produced in a nuclear reactor.…”

Section: Introductionmentioning

confidence: 87%

Development of a radioscandium immunoconjugate for radioimmunotherapy

Moghaddam-Banaem

Jalilian²,

Pourjavid

et al. 2011

Radiochimica Acta

Self Cite

View full text Add to dashboard Cite

Developing monoclonal antibodies labeled with beta-emitters has led to the introduction of important agents in radioimmunotherapy. In this work, Sc-46 chloride was obtained by thermal neutron activation flux of natural metallic scandium sample followed by dissolution in acidic media (radionuclidic purity via beta and gamma ray spectroscopy, 99.9% ; radiochemical purity via ITLC, > 99%) and used in radiolabeling of rituximab after conjugation with DOTA-NHS-ester. The specific activity was however not high. The conjugates were purified by molecular filtration and used in the radiolabeling. The radiochemical purity (ITLC), stability studies (ITLC and size exclusion chromatography), determination of average number of DOTA conjugated per mAb (chelate : antibody ratio, 5.8 : 1) and gel electrophoresis of [ 46 Sc]Sc-DOTA-anti-CD20 were determined followed by biodistribution studies for 46 Sc and [ 46 Sc]Sc-DOTA-anti-CD20 in wild type rats up to 72 h. The binding of the radiolabeled antibody was showed to be 60% on Raji cells. The final compound was stable in presence of PBS at 37 • C and room temperature. The accumulation of the radiolabeled antibody in liver, spleen, kidney, heart and other tissues demonstrates a pattern similar to the other radiolabeled anti-CD20 immunoconjugates. The present study shows the possibility of antibody labeling for future use in radioimmunotherapy by 47 Sc.

show abstract

Development of [64Cu]-DOTA-anti-CD20 for targeted therapy

Cited by 18 publications

References 17 publications

Preparation and biological evaluation of [67Ga]-labeled-superparamagnetic nanoparticles in normal rats

Preparation and biological evaluation of [67Ga]-labeled-superparamagnetic nanoparticles in normal rats

Synthesis and Preclinical Studies of [61Cu]-N-(2-hydroxyacetophenone)glycinate as a Possible PET Radiopharmaceutical

Development of a radioscandium immunoconjugate for radioimmunotherapy

Contact Info

Product

Resources

About